DOCSLIB.ORG

NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19 NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19 Guideline Page Panel Discussion/References Institution Vote and Request YES NO ABSTAIN ABSENT ASTR-1 Based on the data in the noted references, the panel consensus was to include 19 0 2 8 Internal request: Consider everolimus (as an example of an mTOR inhibitor) to be included as an adjuvant everolimus (as an example treatment option for patients with subependymal giant cell astrocytoma (SEGA). of an mTOR inhibitor) to be This is a category 2A recommendation. included as an adjuvant Franz DN, Belousova E, Sparagana S, et al. Everolimus for treatment option for subependymal giant cell astrocytoma in patients with tuberous sclerosis patients with subependymal complex: 2-year open-label extension of the randomised EXIST-1 study. giant cell astrocytoma Lancet Oncol 2014;15:1513-1520. (SEGA). Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381:125-132. LEPT-2 The panel consensus was to include the changes to the treatment algorithms for 18 2 2 7 Internal request: Please leptomeningeal metastases. review the edits made to the treatment algorithms on this page for clarity. BRAIN-D (4 of 13) Based on the data in the noted reference, the panel consensus was to include 15 3 4 7 Internal request: lapatinib + temozolomide as a treatment option for progression of recurrent Should consideration of disease in patients with adult intracranial and/or spinal ependymoma. This is a lapatinib + temozolomide category 2B recommendation. be included as a treatment Gilbert M, Yuan Y, Wani K, et al. AT-23 a phase II study of lapatinib and option for progression of dose-dense temozolomide (TMZ) for adults with recurrent ependymoma: recurrent disease in a CERN clinical trial. Neuro-Oncology 2014;16:v13-v13. patients with adult intracranial and/or spinal ependymoma? NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19 BRAIN-D (7 of 13) Based on the data in the noted reference, the panel consensus was to include 19 2 1 7 Should nivolumab be nivolumab as a treatment option for select patients (eg, patients with small included as a treatment asymptomatic brain metastases) with limited brain metastases from melanoma option for select patients with newly diagnosed disease or stable systemic disease or reasonable systemic (eg, patients with small treatment options. This is a category 2A recommendation. asymptomatic brain Long GV, Atkinson V, Lo S, et al. Combination nivolumab and metastases) with limited ipilimumab or nivolumab alone in melanoma brain metastases: a brain metastases from multicentre randomised phase 2 study. Lancet Oncol 2018;19:672-681. melanoma with newly diagnosed disease or stable systemic disease or reasonable systemic treatment options? BRAIN-D (7 of 13) Based on the data in the noted references, the panel consensus was to include Should nivolumab, the following for select patients (eg, patients with small asymptomatic brain brigatinib (ALK metastases) with limited brain metastases from non-small cell lung cancer with rearrangement-positive newly diagnosed disease or stable systemic disease or reasonable systemic disease only), and ceritinib treatment options: (ALK rearrangement- positive disease only) be Nivolumab (category 2B) 17 5 0 7 included as treatment Gauvain C, Vauleon E, Chouaid C, et al. Intracerebral efficacy and options for select patients tolerance of nivolumab in non-small-cell lung cancer patients with brain (eg, patients with small metastases. Lung Cancer 2018;116:62-66. asymptomatic brain Goldman JW, Crino L, Vokes EE, et al. P2.36: Nivolumab (nivo) in metastases) with limited patients (pts) with advanced (adv) NSCLC and central nervous system brain metastases from non- (CNS) metastases (mets). J Thorac Oncol 2016;11:S238-S239. small cell lung cancer with Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of newly diagnosed disease or nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with stable systemic disease or advanced, refractory squamous non-small-cell lung cancer (CheckMate reasonable systemic 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257-265. treatment options? Brigatinib (ALK rearrangement-positive) (category 2A) 18 2 2 7 Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK- positive non-small-cell lung cancer. N Engl J Med 2018;379:2027-2039. Ceritinib (ALK rearrangement-positive) (category 2B) 16 4 2 7 Kim DW, Mehra R, Tan DSW, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol 2016;17:452-463. NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19 BRAIN-D (7 of 13) Based on the data in the noted references, the panel consensus was to include Should cisplatin/etoposide, the following for patients with recurrent brain metastases from breast cancer (if capecitabine/neratinib, extensive brain metastases, stable systemic disease or reasonable systemic capecitabine/lapatinib, and treatment options exist: paclitaxel/neratinib be included as treatment Capecitabine + lapatinib (HER2-positive) (category 2A) 19 1 2 7 options for patients with Bachelot T, Romieu G, Campone M, et al. Lapatinib plus capecitabine in recurrent brain metastases patients with previously untreated brain metastases from HER2-positive from breast cancer (if metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. extensive brain Lancet Oncol 2013;14:64-71. metastases, stable Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and systemic disease or capecitabine in HER-2 positive breast cancer with brain metastases: A reasonable systemic systematic review and pooled analysis. Eur J Cancer 2017;84:141-148. treatment options exist, HER2-positive disease only Capecitabine + neratinib (HER2-positive) (category 2B) 15 3 4 7 except for Freedman RA, Gelman RS, Melisko ME, et al. TBCRC 022: phase II trial cisplatin/etoposide)? of neratinib + capecitabine for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer brain metastases (BCBM). J Clin Oncol 2017;35:1005-1005. Paclitaxel + neratinib (HER2-positive) (category 2B) 14 5 3 7 Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2- positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol 2016;2:1557-1564. Cisplatin + etoposide (category 2B) 13 4 5 7 Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999;85:1599-1605. Vinolas N, Graus F, Mellado B, et al. Phase II trial of cisplatinum and etoposide in brain metastases of solid tumors. J Neurooncol 1997;35:145-148. NCCN Guidelines for Central Nervous System Cancers V.1.2019 –Follow-Up Email Vote on 01/26/19 BRAIN-D (7 of 13) The panel consensus was to include nivolumab as a treatment option for patients 20 1 1 7 Should nivolumab be with recurrent brain metastases from melanoma (if extensive brain metastases, included as a treatment stable systemic disease or reasonable systemic treatment options exist). This is option for patients with a category 2A recommendation. recurrent brain metastases from melanoma (if extensive brain metastases, stable systemic disease or reasonable systemic treatment options exist)? BRAIN-D (7 of 13) Should pembrolizumab be The panel consensus was to include pembrolizumab as a treatment option for 20 1 1 7 included as a treatment patients with recurrent brain metastases from PD-L1 positive non-small cell lung option for patients with cancer (if extensive brain metastases, stable systemic disease or reasonable recurrent brain metastases systemic treatment options exist). This is a category 2A recommendation. from PD-L1 positive non- Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for small cell lung cancer (if patients with melanoma or non-small-cell lung cancer and untreated extensive brain brain metastases: early analysis of a non-randomized, open-label, phase metastases, stable 2 trial. Lancet Oncol 2016;17:976-983. systemic disease or reasonable systemic treatment options exist)? .
Load more

Recommended publications
  • Clinical Response of the Novel Activating ALK-I1171T
    http://www.diva-portal.org This is the published version of a paper published in Cold Spring Harbor Molecular Case Studies. Citation for the original published paper (version of record): Guan, J., Fransson, S., Siaw, J T., Treis, D., Van den Eynden, J. et al. (2018) Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma o the ALK inhibitor ceritinib Cold Spring Harbor Molecular Case Studies, 4(4): a002550 https://doi.org/10.1101/mcs.a002550 Access to the published version may require subscription. N.B. When citing this work, cite the original published paper. Permanent link to this version: http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-154087 Downloaded from molecularcasestudies.cshlp.org on December 12, 2018 - Published by Cold Spring Harbor Laboratory Press COLD SPRING HARBOR Molecular Case Studies | RESEARCH ARTICLE Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib Jikui Guan,1,2,12 Susanne Fransson,3,12 Joachim Tetteh Siaw,1,12 Diana Treis,4,12 Jimmy Van den Eynden,1 Damini Chand,1 Ganesh Umapathy,1 Kristina Ruuth,5 Petter Svenberg,4 Sandra Wessman,6,7 Alia Shamikh,6,7 Hans Jacobsson,8 Lena Gordon,9 Jakob Stenman,10 Pär-Johan Svensson,10 Magnus Hansson,11 Erik Larsson,1 Tommy Martinsson,3 Ruth H. Palmer,1 Per Kogner,6,7 and Bengt Hallberg1 1Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg 40530, Sweden; 2Children’s Hospital Affiliated to Zhengzhou University,
    [Show full text]
  • ZYKADIA (Ceritinib) RATIONALE for INCLUSION in PA PROGRAM
    ZYKADIA (ceritinib) RATIONALE FOR INCLUSION IN PA PROGRAM Background Zykadia is used in patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC), which is caused by a defect in a gene called anaplastic lymphoma kinase (ALK). Zykadia is a tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells. It is intended for patients with metastatic ALK-positive NSCLC (1). Regulatory Status FDA- approved indication: Zykadia is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (1). Off-Label Uses: (2-3) 1. Inflammatory Myofibroblastic Tumor (IMT) with ALK translocation Zykadia can cause hepatotoxicity therefore liver function tests including AST, ALT and total bilirubin should be monitored at least monthly. Zykadia can cause interstitial lung disease (ILD) or pneumonitis. Zykadia should be permanently discontinued in patients diagnosed with treatment- related ILD/pneumonitis. Zykadia can cause QTc interval prolongation, which requires monitoring of electrocardiograms and electrolytes in patients with congestive heart failure (1). Zykadia is pregnancy category D and may cause fetal harm when administered to a pregnant woman (1). Safety and effectiveness of Zykadia in pediatric patients have not been established (1). Summary Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor that blocks proteins that promote the development of cancerous cells. It is intended for patients with metastatic ALK-positive NSCLC. Safety and effectiveness of Zykadia in patients under 18 years of age have not been established (1). Zykadia FEP Clinical Rationale ZYKADIA (ceritinib) Prior approval is required to ensure the safe, clinically appropriate and cost effective use of Zykadia while maintaining optimal therapeutic outcomes.
    [Show full text]
  • New Drug Update: the Next Step in Personalized Medicine
    New Drug Update: The Next Step in Personalized Medicine Jordan Hill, PharmD, BCOP Clinical Pharmacy Specialist WVU Medicine Mary Babb Randolph Cancer Center Objectives • Review indications for new FDA approved anti- neoplastic medications in 2017 • Outline place in therapy of new medications • Become familiar with mechanisms of action of new medications • Describe adverse effects associated with new medications • Summarize dosing schemes and appropriate dose reductions for new medications First-in-Class Approvals • FLT3 inhibitor – midostaurin • IDH2 inhibitor – enasidenib • Anti-CD22 antibody drug conjugate – inotuzumab ozogamicin • CAR T-cell therapy - tisagenlecleucel “Me-too” Approvals • CDK 4/6 inhibitor – ribociclib and abemaciclib • PD-L1 inhibitors • Avelumab • Durvalumab • PARP inhibitor – niraparib • ALK inhibitor – brigatinib • Pan-HER inhibitor – neratinib • Liposome-encapsulated combination of daunorubicin and cytarabine • PI3K inhibitor – copanlisib Drugs by Malignancy AML Breast Bladder ALL FL Lung Ovarian 0 1 2 3 Oral versus IV 46% 54% Oral IV FIRST-IN CLASS FLT3 Inhibitor - midostaurin Journal of Hematology & Oncology 2017;10:93 Midostaurin (Rydapt®) • 717 newly diagnosed FLT3+ AML Patients • Induction and consolidation chemotherapy and placebo maintenance versus chemotherapy + midostaurin and Treatment maintenance midostaurin • OS: 74.7 mo versus 25.6 mo (P=0.009) Efficacy • EFS: 8.2 mo versus 3.0 mo (P=0.002) • Higher grade > 3 anemia, rash, and nausea Safety N Engl J Med 2017;377:454-64 Midostaurin (Rydapt®) • Approved indications: FLT3+ AML, mast cell leukemia, systemic mastocytosis • AML dose: 50 mg twice daily with food on days 8-21 • Of each induction cycle (+ daunorubicin and cytarabine) • Of each consolidation cycle (+ high dose cytarabine) • ADEs: nausea, myelosuppression, mucositis, increases in LFTs, amylase/lipase, and electrolyte abnormalities • Pharmacokinetics: hepatic metabolism, substrate of CYP 3A4; < 5% excretion in urine RYDAPT (midostaurin) [package insert].
    [Show full text]
  • Clinical Response of the Novel Activating ALK-I1171T Mutation In
    Downloaded from molecularcasestudies.cshlp.org on October 9, 2021 - Published by Cold Spring Harbor Laboratory Press 1 Clinical response of the novel activating ALK-I1171T mutation in 2 neuroblastoma to the ALK inhibitor ceritinib. 3 4 Jikui Guan1*, Susanne Fransson2*, Joachim Tetteh Siaw1*, Diana Treis4*, Jimmy Van den 5 Eynden1, Damini Chand1, Ganesh Umapathy1, Kristina Ruuth9, Petter Svenberg4, Sandra 6 Wessman5, Alia Shamikh5, Hans Jacobsson6, Lena Gordon7, Jakob Stenman8, Pär-Johan 7 Svensson8, Magnus Hansson3, Erik Larsson1, Tommy Martinsson2#, Ruth H. Palmer1#, Per 8 Kogner5#, Bengt Hallberg1#. 9 10 Departments of 1Medical Biochemistry and Cell Biology, 2Pathology and Genetics, 3Pediatrics and 11 Pathology, Institute of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, 12 Gothenburg, Sweden, 4Childhood Cancer Research Unit, Department of Women’s and Children’s 13 Health, and Pediatric Oncology Program Karolinska University Hospital, 5Department of Oncology- 14 Pathology, Karolinska Institutet, and Dept. of Clinical Pathology, Karolinska University Hospital, 15 6Department of Radiology, Karolinska University Hospital, 7Dept. of Pediatric Radiology, Astrid 16 Lindgren Children’s Hospital, Karolinska University Hospital, 8Department of Pediatric Surgery, 17 Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Stockholm, Sweden and 18 9Institute of Molecular Biology, Umeå University, Umeå, Sweden. 19 20 21 Running title: Clinical response to ceritinib in ALK-positive neuroblastoma. 22 23 #Correspondence:
    [Show full text]
  • First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations
    First-Line Treatment Options for Patients with Stage IV Non-Small Cell Lung Cancer with Driver Alterations Patients with stage IV non-small cell lung cancer Nonsquamous cell carcinoma and squamous cell carcinoma Activating EGFR mutation other Sensitizing (L858R/exon 19 MET exon 14 skipping than exon 20 insertion mutations, EGFR exon 20 mutation ALK rearrangement ROS1 rearrangement BRAF V600E mutation RET rearrangement NTRK rearrangement mutations KRAS alterations HER2 alterations NRG1 alterations deletion) EGFR mutation T790M, L858R or Ex19Del PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options PS 0-2 Treatment Options Emerging target; no Emerging target; no Emerging target; no Platinum doublet † † † Osimertinib monotherapy S Afatinib monotherapy M M Alectinib S Entrectinib M Dabrafenib/trametinib M Capmatinib M Selpercatinib M Entrectinib M conclusions available conclusions available conclusions available chemotherapy ± bevacizumab Gefitinib with doublet Standard treatment based on Standard treatment based on Standard treatment based on M M M Brigatinib S Crizotinib M M Tepotinib M Pralsetinib* W Larotrectinib M chemotherapy non-driver mutation guideline non-driver mutation guideline non-driver mutation guideline If alectinib or brigatinib are not available If entrectinib or crizotinib are not available Standard treatment based on Standard treatment based on Standard treatment based on Dacomitinib monotherapy M Osimertinib W M M M Ceritinib S Ceritinib W non-driver mutation guideline non-driver mutation guideline non-driver mutation guideline Monotherapy with afatinib M Crizotinib S Lortlatinib W Standard treatment based on Erlotinib/ramucirumab M M non-driver mutation guideline Erlotinib/bevacizumab M Monotherapy with erlotinib M Strength of Recommendation Monotherapy with gefitinib M S Strong M Moderate W Weak Monotherapy with icotinib M Notes.
    [Show full text]
  • Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?
    cancers Review Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? Tri Le 1 and David E. Gerber 1,2,3,* 1 Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA; [email protected] 2 Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA 3 Division of Hematology-Oncology, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX 75390-8852, USA * Correspondence: [email protected]; Tel.: +1-214-648-4180; Fax: +1-214-648-1955 Received: 15 January 2019; Accepted: 4 March 2019; Published: 15 March 2019 Abstract: The FLAURA trial established osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), as a viable first-line therapy in non-small cell lung cancer (NSCLC) with sensitizing EGFR mutations, namely exon 19 deletion and L858R. In this phase 3 randomized, controlled, double-blind trial of treatment-naïve patients with EGFR mutant NSCLC, osimertinib was compared to standard-of-care EGFR TKIs (i.e., erlotinib or gefinitib) in the first-line setting. Osimertinib demonstrated improvement in median progression-free survival (18.9 months vs. 10.2 months; hazard ratio 0.46; 95% CI, 0.37 to 0.57; p < 0.001) and a more favorable toxicity profile due to its lower affinity for wild-type EGFR. Furthermore, similar to later-generation anaplastic lymphoma kinase (ALK) inhibitors, osimertinib has improved efficacy against brain metastases. Despite this impressive effect, the optimal sequencing of osimertinib, whether in the first line or as subsequent therapy after the failure of earlier-generation EGFR TKIs, is not clear.
    [Show full text]
  • ALK Tyrosine Kinase Inhibitors, 5.01.538
    PHARMACY POLICY – 5.01.538 ALK Tyrosine Kinase Inhibitors Effective Date: June 1, 2021 RELATED MEDICAL POLICIES: Last Revised: May 20, 2021 None Replaces: N/A Select a hyperlink below to be directed to that section. POLICY CRITERIA | CODING | RELATED INFORMATION EVIDENCE REVIEW | REFERENCES | HISTORY ∞ Clicking this icon returns you to the hyperlinks menu above. Introduction The anaplastic lymphoma kinase (ALK) gene provides instructions for making a specific kind of protein called ALK receptor tyrosine kinase. This protein helps cells communicate. When this gene is damaged, cell growth can get stuck in the “on” position and cells grow uncontrollably. Changes to the ALK gene can lead to non-small-cell lung cancer. Tyrosine kinase inhibitors block specific enzymes, essentially working to turn the cell growth to the “off” position. ALK tyrosine kinase inhibitors specifically targets cancers caused by changes to the ALK gene. This policy describes when this specific form of chemotherapy may be considered medically necessary. Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered. Policy Coverage Criteria Drug Medical Necessity Alecensa® (alectinib) Alecensa® (alectinib) may be considered medically necessary for the treatment of adult patients with advanced or Drug Medical Necessity metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive.
    [Show full text]
  • Brigatinib Combined with Anti-EGFR Antibody Overcomes Osimertinib Resistance in EGFR-Mutated Non-Small-Cell Lung Cancer
    ARTICLE Received 29 Sep 2016 | Accepted 30 Jan 2017 | Published 13 Mar 2017 DOI: 10.1038/ncomms14768 OPEN Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer Ken Uchibori1,2, Naohiko Inase2, Mitsugu Araki3, Mayumi Kamada4, Shigeo Sato1, Yasushi Okuno3,4, Naoya Fujita1 & Ryohei Katayama1 Osimertinib has been demonstrated to overcome the epidermal growth factor receptor (EGFR)-T790M, the most relevant acquired resistance to first-generation EGFR–tyrosine kinase inhibitors (EGFR–TKIs). However, the C797S mutation, which impairs the covalent binding between the cysteine residue at position 797 of EGFR and osimertinib, induces resistance to osimertinib. Currently, there are no effective therapeutic strategies to overcome the C797S/T790M/activating-mutation (triple-mutation)-mediated EGFR–TKI resistance. In the present study, we identify brigatinib to be effective against triple-mutation-harbouring cells in vitro and in vivo. Our original computational simulation demonstrates that brigatinib fits into the ATP-binding pocket of triple-mutant EGFR. The structure–activity relationship analysis reveals the key component in brigatinib to inhibit the triple-mutant EGFR. The efficacy of brigatinib is enhanced markedly by combination with anti-EGFR antibody because of the decrease of surface and total EGFR expression. Thus, the combination therapy of brigatinib with anti-EGFR antibody is a powerful candidate to overcome triple-mutant EGFR. 1 Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan. 2 Department of Respiratory Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan.
    [Show full text]
  • Zykadia (Ceritinib)
    Zykadia® (ceritinib) – New formulation approval • On March 18, 2019, the FDA approved Novartis’ Zykadia (ceritinib) tablets, for the treatment of adults with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase- positive as detected by an FDA-approved test. — Zykadia is also available as capsules for the same indication. • The approval of Zykadia tablets was based on studies conducted with Zykadia capsules. • Warnings and precautions of Zykadia include gastrointestinal adverse reactions, hepatotoxicity, interstitial lung disease/pneumonitis, QT interval prolongation, hyperglycemia, bradycardia, pancreatitis, and embryo-fetal toxicity. • The most common adverse reactions (≥ 25%) with the use of Zykadia 450 mg with food were diarrhea, nausea, abdominal pain vomiting, and fatigue; and with Zykadia 750 mg under fasted conditions were diarrhea, nausea, vomiting, fatigue, abdominal pain, decreased appetite, and weight loss. • The recommended dose of Zykadia tablets or capsules is 450 mg orally once daily with food until disease progression or unacceptable toxicity. • Novartis’ launch plans for Zykadia tablets are pending. Zykadia tablets will be available in a strength of 150 mg. optumrx.com OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at optum.com. All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners. This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx. RxNews® is published by the OptumRx Clinical Services Department.
    [Show full text]
  • Systemic Therapy Update
    Systemic Therapy Update Volume 24 Issue 2 February 2021 For Health Professionals Who Care for Cancer Patients Inside This Issue: Editor’s Choice Revised Protocols, PPPOs and Patient Handouts COVID-19 Vaccine Guidance | New Programs: Ribociclib BR: BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJACTW, BRAJCAP, and Fulvestrant for Advanced Breast Cancer BRAJLHRHAI, BRAJLHRHT, BRAJTTW, BRAVCAP, BRAVCLOD, BRAVEVEX, (UBRAVRBFLV) | Bevacizumab, Cisplatin and Paclitaxel for BRAVGEMT, BRAVLCAP, BRAVLHRHA, BRAVLHRHT, UBRAVPALAI, BRAVPTRAT, Gynecologic Malignancies (GOCISPBEV) | Gemtuzumab UBRAVRIBAI, BRAVTAX, BRAVTCAP, BRAVTW, BRLACTWAC, BRLATACG, BRLATWAC | GI: GIAAVCT, GIAJCAP, GIAJCAPOX, GIAJFFOX, GIAJRALOX, Ozogamicin with Chemotherapy for AML (ULKGEMOZ) | GIAVCAP, GIAVCAPB, GIAVCRT, GIAVTZCAP, GICAPIRI, GICAPOX, GICART, Bortezomib, Lenalidomide and Dexamethasone for GICIRB, GICOXB, GICPART, GIEFFOXRT, GIENACTRT, GIFFIRB, GIFFOXB, Untreated Multiple Myeloma (UMYBLDF) | Paclitaxel for UGIFFOXPAN, GIFIRINOX, GIFOLFOX, GIGAJCOX, GIGAJCPRT, GIGAJFFOX, Metastatic Angiosarcoma (SAAVTW) | Cemiplimab for GIGAVCC, GIGAVCCT, GIGAVCFT, GIGAVCOX, GIGAVCOXT, GIGAVFFOX, Cutaneous Squamous Cell Carcinoma (USMAVCEM) GIGAVFFOXT, GIGAVRAMT, GIGECC, GIGFLODOC, UGINETEV, GIPAJFIROX, GIPAJGCAP, GIPAVCAP, GIPNEVER, GIRAJCOX, GIRAJFFOX, GIRCAP, GIRCRT, Drug Update GIRINFRT | GO: GOCABR, GOCABRBEV, GOCISP, GOCXAJCAT, GOCXCAT, IV Famotidine to Replace IV Ranitidine GOCXCATB, GOCXCRT, GOENDCAT, GOOVBEVLD, GOOVBEVP, GOOVCATB, Medication Safety Corner GOOVCATM, GOOVCATR,
    [Show full text]
  • Zykadia) for Metastatic Non-Small Cell Lung Cancer
    pan-Canadian Oncology Drug Review Final Clinical Guidance Report Ceritinib (Zykadia) for Metastatic Non-Small Cell Lung Cancer December 3, 2015 DISCLAIMER Not a Substitute for Professional Advice This report is primarily intended to help Canadian health systems leaders and policymakers make well-informed decisions and thereby improve the quality of health care services. While patients and others may use this report, they are made available for informational and educational purposes only. This report should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision making process, or as a substitute for professional medical advice. Liability pCODR does not assume any legal liability or responsibility for the accuracy, completeness or usefulness of any information, drugs, therapies, treatments, products, processes, or services disclosed. The information is provided "as is" and you are urged to verify it for yourself and consult with medical experts before you rely on it. You shall not hold pCODR responsible for how you use any information provided in this report. Reports generated by pCODR are composed of interpretation, analysis, and opinion on the basis of information provided by pharmaceutical manufacturers, tumour groups, and other sources. pCODR is not responsible for the use of such interpretation, analysis, and opinion. Pursuant to the foundational documents of pCODR, any findings provided by pCODR are not binding on any organizations, including funding bodies. pCODR hereby disclaims any and all liability for the use of any reports generated by pCODR (for greater certainty, "use" includes but is not limited to a decision by a funding body or other organization to follow or ignore any interpretation, analysis, or opinion provided in a pCODR report) FUNDING The pan-Canadian Oncology Drug Review is funded collectively by the provinces and territories, with the exception of Quebec, which does not participate in pCODR at this time.
    [Show full text]
  • Rapidly Changing Treatment Algorithms for Metastatic Nonsquamous Non-Small-Cell Lung Cancer
    RAPIDLY CHANGING ALGORITHMS FOR NONSQUAMOUSREVIEW NSCLC, ARTICLE Melosky Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer B. Melosky MD* ABSTRACT Background The treatment paradigm for metastatic nonsquamous non-small-cell lung cancer (nsclc) continues to change. Algorithms published only 6 months ago are outdated today and are dramatically different from those published a few years ago. New driver mutations continue to be identified, and the development of therapies to inhibit oncogenic addiction is ongoing. Patient survival is improving as treatments become more personalized and effective. Methods This review looks at the outcomes of recent trials and discusses treatment options for patients with metastatic nsclc of nonsquamous histology. Algorithms continue to change quickly, and an attempt is made to keep the paradigm current and applicable into the near future. Results Treatment algorithms for nsclc tumours with EGFR mutations, ALK rearrangements, and ROS1 rearrangements, and for wild-type tumours are presented. A future algorithm based on new immunotherapy data is proposed. Conclusions The treatment algorithm for EGFR mutation is changing with the proven efficacy of osimertinib for the acquired T790M mutation. All patients taking first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors must be tested. The treatment algorithm for ALK rearrangement has changed with the proven superiority of alectinib compared with crizotinib in the first-line setting. The approval of crizotinib for ROS1 rearrangements now means that patients also must be tested for that mutation. The biomarker for checkpoint inhibitors continues to be PD-L1 by immunohistochemistry stain, but whether testing will be necessary for patient selection if chemotherapy combinations are implemented will be determined soon.
    [Show full text]